New Jersey recently made changes to what is known as the Mansion Tax. New Jersey imposes an additional tax on the transfer of certain types of real estate when the sales price exceeds $1 million. Until recently, that tax was 1%. Under new legislation, that tax is now between 1% and 3.5%, depending on the sales price.
Owners of Class 4A commercial real estate have not been able to escape this tax by transferring an entity that owns real estate rather than the real estate itself. Instead of being called the Mansion Tax, this tax is called the Controlling Interest Transfer Tax (CITT).
What Are the Changes?
The new bill (P.L. 2025, c. 69) adds four more tiers as follows:
Sale Price
CITT
$1 million to $2 million
1.0%
Over $2 million to $2.5 million
2.0%
Over $2.5 million to $3 million
2.5%
Over $3 million to $3.5 million
3.0%
Over $3.5 million
3.5%
Need to Know
The new law makes it clear that the tax is imposed on the seller of the property. The new tax applies to real estate contracts executed on or after July 10, 2025. For the tax NOT to apply, the contract would have had to have been executed before July 10, 2025, AND the deed must be recorded prior to November 15, 2025.
These rules apply to Class 4A commercial property owned by an entity. There are more rules and details that may have to be considered, depending on the nature of your transaction.
New Jersey Legislature Passes “Power NJ Act” Clearing Path for Advanced Nuclear Energy Development
On June 30, 2026, the New Jersey Assembly and Senate both approved the “Power NJ Act” (A4881), sending the legislation to Governor Sherrill for signature after unanimous, bipartisan approval. The Power NJ Act would direct the New Jersey Board of Public Utilities, in partnership with the New Jersey Economic Development Authority, to establish a program […]
NJ Supreme Court Confirms Personal Email Is Within OPRA's Reach: What Boards, Municipalities, Public Officials and Public Entities Must Do Now
If Your Public Officials Conduct Public Business on Personal Accounts, Those Communications May Be Subject to Disclosure under the New Jersey Open Public Records Act (N.J.S.A. 47:1A-1 et seq.). A recent New Jersey Supreme Court decision has direct consequences for every board of education, municipality, and public agency in the state. In Rosetti v. Ramapo-Indian […]
On June 15, 2026, NJDEP adopted final PFAS remediation standards for PFNA, PFOA, PFOS, and GenX, converting interim criteria into enforceable requirements. NJDEP has adopted final remediation standards for PFNA, PFOA, PFOS, and GenX, converting interim criteria into enforceable requirements under N.J.A.C. 7:9C, 7:26D, and 7:26E. The rule establishes a groundwater standard for GenX, incorporates […]
IRS Refund Deadline Approaches: Taxpayers Should Consider Filing Protective Claims Before July 10, 2026
A recent Court of Federal Claims decision may entitle taxpayers to refunds of interest and penalties paid on federal tax obligations that came due during the COVID-19 disaster period. The IRS refund deadline tied to that ruling is July 10, 2026, and eligible taxpayers should consider filing a protective claim before it expires. On March […]
NJ Family Leave Act 2026 Amendments: What Small Businesses Must Do Before July 17
Small Business, Big Leave: New Coverage Rules, Lower Eligibility Thresholds, and Expanded Reinstatement Rights If your New Jersey business has 15 or more employees, you will soon be required to provide job-protected family leave under state law. Effective July 17, 2026, the NJ Family Leave Act amendments lower the coverage threshold from 30 employees to […]
DOJ and DEA Order Immediately Reschedules FDA-Approved and State-Licensed Medical Cannabis to Schedule III: What Operators Need to Know
On April 23, 2026, the United States Department of Justice and the Drug Enforcement Administration announced an order that marks the most consequential shift in federal cannabis policy in more than five decades. Acting Attorney General Todd Blanche signed an order that immediately places both FDA-approved cannabis products and state-regulated medical cannabis products into Schedule […]
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Sign up to get the latest from our attorneys!
Explore What Matters Most to You.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!
